Literature DB >> 11738392

Amplification of c-myc gene and overexpression of c-Myc protein in breast cancer and adjacent non-neoplastic tissue.

P Chrzan1, J Skokowski, A Karmolinski, T Pawelczyk.   

Abstract

BACKGROUND: Deregulated c-Myc expression and alterations of c-myc oncogene have been reported to play an important role in breast cancer tumorigenesis. We examined the relationship between c-Myc protein level, amplification of c-myc oncogene and commonly used clinical and pathologic factors.
METHODS: The studies were conducted on 94 ductal and lobular cancers. Amplification of c-Myc was assessed by the semiquantitative multiplex PCR assay. The amount of c-Myc protein was estimated by the densitometry analysis of Western blots.
RESULTS: Amplification of c-Myc was found in 21% of examined cancers. There was no association of c-myc amplification with established risk factors. Overexpression of c-Myc protein without c-myc amplification was associated with negative status of axillary lymph node. The size of lobular carcinoma displaying overexpression of c-Myc and the normal copy number of c-myc gene was significantly smaller than the size of tumor with elevated c-Myc and amplification of c-myc gene (p < 0.01). Within tumors displaying overexpression of c-Myc protein and c-myc gene amplification the size of ductal carcinoma was smaller than the size of lobular carcinoma (p < 0.007).
CONCLUSION: Data presented in this study suggest that alterations of c-myc gene and c-Myc protein level might be related to breast cancer progression. The prognostic utility of elevated level of c-Myc protein associated with normal status of c-myc gene for patients with lobular carcinoma requires further studies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11738392     DOI: 10.1016/s0009-9120(01)00260-0

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  31 in total

1.  EMT reversal in human cancer cells after IR knockdown in hyperinsulinemic mice.

Authors:  Zara Zelenko; Emily Jane Gallagher; Irini Markella Antoniou; Deepali Sachdev; Anupma Nayak; Douglas Yee; Derek LeRoith
Journal:  Endocr Relat Cancer       Date:  2016-07-19       Impact factor: 5.678

2.  18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers.

Authors:  Nicolaos Palaskas; Steven M Larson; Nikolaus Schultz; Evangelia Komisopoulou; Justin Wong; Dan Rohle; Carl Campos; Nicolas Yannuzzi; Joseph R Osborne; Irina Linkov; Edward R Kastenhuber; Richard Taschereau; Seema B Plaisier; Chris Tran; Adriana Heguy; Hong Wu; Chris Sander; Michael E Phelps; Cameron Brennan; Elisa Port; Jason T Huse; Thomas G Graeber; Ingo K Mellinghoff
Journal:  Cancer Res       Date:  2011-06-06       Impact factor: 12.701

3.  Myc Is Required for Adaptive β-Cell Replication in Young Mice but Is Not Sufficient in One-Year-Old Mice Fed With a High-Fat Diet.

Authors:  Carolina Rosselot; Anil Kumar; Jayalakshmi Lakshmipathi; Pili Zhang; Geming Lu; Liora S Katz; Edward V Prochownik; Andrew F Stewart; Luca Lambertini; Donald K Scott; Adolfo Garcia-Ocaña
Journal:  Diabetes       Date:  2019-07-10       Impact factor: 9.461

4.  MicroRNA-based screens for synthetic lethal interactions with c-Myc.

Authors:  Youjun Li; Yahui Zhu; Edward V Prochownik
Journal:  RNA Dis       Date:  2016-05-30

Review 5.  MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers.

Authors:  Nandini Dey; Brian Leyland-Jones; Pradip De
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

6.  Cooverexpression of EpCAM and c-myc genes in malignant breast tumours.

Authors:  Samira Sadeghi; Zohreh Hojati; Hossein Tabatabaeian
Journal:  J Genet       Date:  2017-03       Impact factor: 1.166

Review 7.  c-Myc oncoprotein: a dual pathogenic role in neoplasia and cardiovascular diseases?

Authors:  Claudio Napoli; Lilach O Lerman; Filomena de Nigris; Vincenzo Sica
Journal:  Neoplasia       Date:  2002 May-Jun       Impact factor: 5.715

8.  Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.

Authors:  Mahnaz Janghorban; Amy S Farrell; Brittany L Allen-Petersen; Carl Pelz; Colin J Daniel; Jessica Oddo; Ellen M Langer; Dale J Christensen; Rosalie C Sears
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-09       Impact factor: 11.205

9.  Differential gene regulation by the SRC family of coactivators.

Authors:  Hua Zhang; Xia Yi; Xiaojing Sun; Na Yin; Bin Shi; Huijian Wu; Dan Wang; Ge Wu; Yongfeng Shang
Journal:  Genes Dev       Date:  2004-07-15       Impact factor: 11.361

Review 10.  MYC in breast tumor progression.

Authors:  Yinghua Chen; Olufunmilayo I Olopade
Journal:  Expert Rev Anticancer Ther       Date:  2008-10       Impact factor: 4.512

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.